Methylphenidate as a treatment option for substance use disorder
A transdiagnostic perspective
Bibliographic Data
| ID | 15520738 |
|---|---|
| Authors | Peter van Ruitenbeek (0000-0002-3802-6551, Maastricht University, corresponding author), Luisa Franzen (Maastricht University), Natasha L Mason (0000-0001-7115-0389, Maastricht University), Peter Stiers (Maastricht University), Johannes G Ramaekers (0000-0003-4553-376X, Maastricht University) |
| Year | 2023 |
| Volume | 14 |
| Pages | 1208120-1208120 |
| Publication date | 2023-08-03 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2023.1208120 |
| PMID | 37599874 |
| OpenAlex | W4385520533 |
| Language | EN |
| References cited | 26 |
A transition in viewing mental disorders from conditions defined as a set of unique characteristics to one of the quantitative variations on a collection of dimensions allows overlap between disorders. The overlap can be utilized to extend to treatment approaches. Here, we consider the overlap between attention-deficit/hyperactivity disorder and substance use disorder to probe the suitability to use methylphenidate as a treatment for substance use disorder. Both disorders are characterized by maladaptive goal-directed behavior, impaired cognitive control, hyperactive phasic dopaminergic neurotransmission in the striatum, prefrontal hypoactivation, and reduced frontal cortex gray matter volume/density. In addition, methylphenidate has been shown to improve cognitive control and normalize associated brain activation in substance use disorder patients and clinical trials have found methylphenidate to improve clinical outcomes. Despite the theoretical basis and promising, but preliminary, outcomes, many questions remain unanswered. Most prominent is whether all patients who are addicted to different substances may equally profit from methylphenidate treatment
Clinical trial · Cognition · Methylphenidate · Prefrontal cortex · Psychiatry · Attention Deficit Hyperactivity Disorder · Clinical Psychology · Medicine · Neural and Behavioral Psychology Studies · Neuroscience · Neurotransmitter Receptor Influence on Behavior · Psychology
Characterization of the decision-making deficit of patients with ventromedial prefrontal cortex lesions
Drug Addiction
Neurobiologic Advances from the Brain Disease Model of Addiction
The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology
Development of a rational scale to assess the harm of drugs of potential misuse
Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015
Neural systems of reinforcement for drug addiction
Insensitivity to future consequences following damage to human prefrontal cortex
Dissecting components of reward
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Decision making, impulse control and loss of willpower to resist drugs
Advancing understanding of executive function impairments and psychopathology
Enhanced Amygdala-Striatal Functional Connectivity during the Processing of Cocaine Cues in Male Cocaine Users with a History of Childhood Trauma
Stop What You're Doing!—An fMRI Study on Comparisons of Neural Subprocesses of Response Inhibition in ADHD and Alcohol Use Disorder
Monetary Reward Discounting, Inhibitory Control, and Trait Impulsivity in Young Adults With Internet Gaming Disorder and Nicotine Dependence
Computational analysis of probabilistic reversal learning deficits in male subjects with alcohol use disorder
Liking, wanting, and the incentive-sensitization theory of addiction
| Highly cited | No |
|---|